Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer

Iacovelli, Roberto*,†; Ciccarese, Chiara†,‡; Brunelli, Matteo§; Bogina, Giuseppe; Munari, Enrico; Bimbatti, Davide*; Mosillo, Claudia*; Fantinel, Emanuela*; Bria, Emilio*,‡; Martignoni, Guido§,¶; Tortora, Giampaolo*,‡

doi: 10.1097/CJI.0000000000000287
Clincal Studies
Buy

De novo metastatic castration-sensitive prostate cancer (mCSPC) is small subgroup of prostate cancer associated with poor prognosis. The aim of our study was to assess the expression of programmed death-ligand 1 (PD-L1) in tumor cells of de novo mCSPC patients. Patients referred to our institution from January 2007 to October 2017 with de novo mCSPC and available diagnostic tissue were included. We tested the PD-L1 pharmaDx qualitative immunohistochemical assay, a monoclonal rabbit anti-PD-L1, clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed paraffin-embedded. Kaplan-Meier method was used to estimate survivals according to the expression of PD-L1. The study population included 32 de novo mCSPC patients, analyzed for PD-L1 expression using 2 cut-off values (1% and 5%) to define the positivity. Total of 46.9% of cases had tumor PD-L1 expression ≥1%, and 31.3% had expression ≥5%. No differences were found between the PD-L1 expression ≥1% and the involvement of liver, lung, and number of bone metastases, and the disease volume based on CHAARTED classification. PD-L1 tumors had higher incidence of Gleason score ≥8 compared with PD-L1+ tumors (P=0.037), while the incidence of lymph node metastases was higher in PD-L1+ tumors (P=0.044). No difference in the median overall survival (mOS) was observed between the PD-L1 population and the PD-L1+ patients (43.8 vs. 29.6 mo; P=0.88). The tumor PD-L1 expression cannot be considered a prognostic factor for de novo mCSPC, even if its prognostic and predictive significance have to be thoroughly investigated to better define the selected group of prostate cancer patients that might benefit from checkpoint blockade immunotherapy.

*Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Oncologia Medica, Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Roma

Oncologia Medica, Azienda Ospedaliera Universitaria Integrata (AOUI)

§Department of Diagnostics and Public Health, University of Verona

Pathology Unit, Ospedale Sacrocuore, Negrar, Verona

Pathology Unit, Pederzoli Hospital, Peschiera del Garda, Italy

R.I. and C.C. share the first co-authorship.

Reprints: Roberto Iacovelli, Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Oncologia Medica, Largo A. Gemelli, 8, Roma 00168, Italy (e-mails: roberto.iacovelli@policlinicogemelli.it; roberto.iacovelli@alice.it).

Received October 12, 2018

Accepted April 8, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.